Description General description A cell-permeable, reversible, and ATP-competitive cytokine-suppressive anti-inflammatory drug (CSAID). A bicyclic imidazole that inhibits lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production (IC50 = 1 µM). Also acts as an inhibitor of both cyclooxygenase and 5-lipoxygenase. SKF-86002 also acts as a specific p38 MAP kinase inhibitor. A cytokine-suppressive anti-inflammatory drug (CSAID). A bicyclic imidazole that inhibits lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production (IC50 = 1 µM). Also acts as an inhibitor of both cyclooxygenase and 5-lipoxygenase. SKF-86002 also acts as a specific p38 MAP kinase inhibitor. Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target (LPS)-stimulated IL-1 and TNF-α production Product competes with ATP. Reversible: yes Target IC50: 1 µM inhibiting lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production Warning Toxicity: Irritant (B) Other Notes Frasch, S.C., et al. 1998. J. Biol. Chem. 273, 8389. Blanque, R., et al. 1997. Drugs Exp. Clin. Res. 23, 63. Lee, J.C., et al. 1995. Nature 372, 739. Prichett, W., et al. 1995. J. Inflamm. 45, 97. Lee, J.C., et al. 1993. Ann. N.Y. Acad. Sci. 696, 149.